GENE ONLINE|News &
Opinion
Blog

2022-07-04| Licensing

Akebia Therapeutics Gains $55M Following Deal Termination by Otsuka Pharmaceutical

by Fujie Tham
Share To

Otsuka Pharmaceutical agreed to pay Cambridge, Massachusetts-based Akebia Therapeutics $55 million for terminating the vadadustat oral anemia drug’s licensing deal following rejection by the FDA.

As a result of the termination, the biotech is regaining rights from Otsuka for vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor inside and outside the US. Earlier this May, the FDA issued a complete response letter in response to vadadustat’s safety concerns, deeming the drug is not ready for approval.

Related article: FDA Halts Sanofi’s $3.7B Multiple Sclerosis Investment

 

Otsuka Terminates Deal Following Safety Issues 

 

FDA concluded that the data in vadadustat’s New Drug Application (NDA) showed increased risk of cardiovascular issues (thromboembolic events) and drug-induced liver injury. FDA said that Akebia could explore ways to potentially demonstrate a favorable benefit-risk assessment through new clinical trials.

A few weeks later, Otsuka decided to drop the medicine, causing disputes between both companies. Otsuka alleged breaches that could lead to a premature termination of the partnership, while Akebia denies said claims.

“Otsuka has been a strong partner for many years, and we appreciate their desire to have an efficient transfer of the responsibilities back to Akebia. We plan to continue to pursue approval for vadadustat to make it available to patients in these territories, and we are excited about the potential additional value this brings to Akebia, as we continue to work to build the company into the future,” said John Butler, Akebia CEO.

Vadadustat is currently under review by the European Medicines Agency (EMA) for treating anemia due to chronic kidney disease in adults. In Japan, the drug is approved for chronic kidney disease anemia in both dialysis and non-dialysis dependent adults.

For Akebia, this cash injection is a significant sum, making the smaller biotech better funded than competitors on a similar scale. Following the news, Akebia’s share price jumped 50%, crossing the $0.50 mark.

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
In Response to Expanding Monkeypox Outbreak, FDA Approves Emergency Use of JYNNEOS Vaccine
2022-08-11
FDA Finds Carcinogen In Merck’s Diabetes Drug, Allows Continued Sales To Avoid Shortage
2022-08-11
Verona’s COPD Candidate Scores Clinical Win, Paving the Way for FDA Submission
2022-08-10
LATEST
Vaccine Protecting Against 20 Different Pneumococcal Infections Proves Effective in Trial
2022-08-12
FDA Approves Roche’s Established Antiviral For Children Aged Five Or Older
2022-08-12
Novartis Reported Two Deaths Following Zolgensma Gene Therapy
2022-08-12
Extreme Climate Change Is Aggravating Infectious Diseases!
2022-08-11
In Response to Expanding Monkeypox Outbreak, FDA Approves Emergency Use of JYNNEOS Vaccine
2022-08-11
Potential $1 billion Acquisition of TeneoTwo by AstraZeneca comes to Fruition
2022-08-11
Gene Repair Therapy: First Patient Dosed With New Treatment for Sickle Cell Disease
2022-08-11
EVENT
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-20
Cell & Gene Therapy USA 2022
Virtual
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!